GLP Watchdog

GoodRx vs Hers

Hers has an open FDA warning letter dated September 9, 2025. GoodRx has none. No price lines up like for like. They share brand-name tirzepatide pen, but Hers' $299 covers the medication only, with a separate membership on top.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Hers

GoodRx logo

GoodRx

7.8/10

Hers logo

Hers

6.8/10

FDA warning letters
None on record
Pharmacy
Brand-name only; no compounding
Lowest standing price
$149/moFoundayo (orforglipron) pill
$199/moCompounded semaglutide injection
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit GoodRx
Visit Hers

Neither GoodRx nor Hers pays us. Links to them earn nothing. Scores: GoodRx 7.8, Hers 6.8. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. GoodRx has none.

  2. 02

    Hers names three pharmacies. GoodRx sells brand-name medication only.

  3. 03

    No price lines up like for like. They share brand-name tirzepatide pen, but Hers' $299 covers the medication only, with a separate membership on top.

  4. 04

    Only GoodRx lists a price for Foundayo (orforglipron) pill. Only Hers lists a price for compounded semaglutide injection.

  5. 05

    Hers covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Hers

Brand-name tirzepatide pen

$299/mo

$3,588 a year

$299/mo

medication only, membership extra; not compared

Compounded semaglutide injection
Not sold or not priced

$199/mo

$2,388 a year

Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
Services and medication are generally non-refundable
No refund guaranteed once the pharmacy has processed an order

Read off each seller’s own pages. GoodRx: October 30, 2026. Hers: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • No FDA warning letter on record
  • Sells Foundayo (orforglipron) pill, which Hers does not price
Visit GoodRx

The case for Hers

6.8/10
  • Sells compounded semaglutide injection, which GoodRx does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

Scores

GoodRx 7.8 · Hers 6.8 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
7.0

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Hers: questions

Hers has an open FDA warning letter dated September 9, 2025. GoodRx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. GoodRx sells brand-name medication only.
No price lines up like for like. They share brand-name tirzepatide pen, but Hers' $299 covers the medication only, with a separate membership on top. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order.
Neither GoodRx nor Hers pays us. Links to them earn nothing. Scores: GoodRx 7.8, Hers 6.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks